Hubbry Logo
search
logo
Astrocyte avatar
Astrocyte
Astrocyte
current hub
2117499

Astrocyte

logo
Community Hub0 Subscribers
Read side by side
Astrocyte
View on Wikipedia
from Wikipedia
Astrocyte
An astrocyte from a rat brain grown in tissue culture and stained with antibodies to GFAP (red) and vimentin (green). Both proteins are present in large amounts in the intermediate filaments of this cell, so the cell appears yellow. The blue material shows DNA visualized with DAPI stain, and reveals the nucleus of the astrocyte and of other cells. Image courtesy of EnCor Biotechnology Inc.
Details
PrecursorGlioblast
LocationBrain and spinal cord
Identifiers
Latinastrocytus
MeSHD001253
NeuroLex IDsao1394521419
THH2.00.06.2.00002, H2.00.06.2.01008
FMA54537
Anatomical terms of microanatomy

Astrocytes (from Ancient Greek ἄστρον, ástron, "star" and κύτος, kútos, "cavity", "cell"), also known collectively as astroglia, are characteristic star-shaped glial cells in the brain and spinal cord. They perform many functions, including biochemical control of endothelial cells that form the blood–brain barrier,[1] provision of nutrients to the nervous tissue, maintenance of extracellular ion balance, regulation of cerebral blood flow, and a role in the repair and scarring process of the brain and spinal cord following infection and traumatic injuries.[2] The proportion of astrocytes in the brain is not well defined; depending on the counting technique used, studies have found that the astrocyte proportion varies by region and ranges from 20% to around 40% of all glia.[3] Another study reports that astrocytes are the most numerous cell type in the brain.[2] Astrocytes are the major source of cholesterol in the central nervous system.[4] Apolipoprotein E transports cholesterol from astrocytes to neurons and other glial cells, regulating cell signaling in the brain.[4] Astrocytes in humans are more than twenty times larger than in rodent brains, and make contact with more than ten times the number of synapses.[5]

Research since the mid-1990s has shown that astrocytes propagate intercellular Ca2+ waves over long distances in response to stimulation, and, similar to neurons, release transmitters (called gliotransmitters) in a Ca2+-dependent manner.[6] Data suggest that astrocytes also signal to neurons through Ca2+-dependent release of glutamate.[7] Such discoveries have made astrocytes an important area of research within the field of neuroscience.

Structure

[edit]
Astrocytes (green) in the context of neurons (red) in a mouse cortex cell culture
23-week-old fetal brain culture human astrocyte
Astrocytes (red-yellow) among neurons (green) in the living cerebral cortex

Astrocytes are a sub-type of glial cells in the central nervous system. They are also known as astrocytic glial cells. Star-shaped, their many processes envelop synapses made by neurons. In humans, a single astrocyte cell can interact with up to 2 million synapses at a time.[8] Astrocytes are classically identified using histological analysis; many of these cells express the intermediate filament glial fibrillary acidic protein (GFAP).[9]

Types

[edit]

Several forms of astrocytes exist in the central nervous system: including fibrous (in white matter), protoplasmic (in grey matter), and radial.

Fibrous glia

[edit]

The fibrous glia are usually located within white matter, have relatively few organelles, and exhibit long unbranched cellular processes. This type often has astrocytic endfeet processes that physically connect the cells to the outside of capillary walls when they are in proximity to them.[10]

Protoplasmic glia

[edit]

The protoplasmic glia are the most prevalent and are found in grey matter tissue, possess a larger quantity of organelles, and exhibit short and highly branched tertiary processes.[citation needed]

Radial glia

[edit]

The radial glial cells are disposed in planes perpendicular to the axes of ventricles. One of their processes abuts the pia mater, while the other is deeply buried in gray matter. Radial glia are mostly present during development, playing a role in neuron migration. Müller cells of the retina and Bergmann glia cells of the cerebellar cortex represent an exception, being present still during adulthood. When in proximity to the pia mater, all three forms of astrocytes send out processes to form the pia-glial membrane.

Energy use

[edit]

Early assessments of energy use in gray matter signaling suggested that 95% was attributed to neurons and 5% to astrocytes.[11] However, after discovering that action potentials were more efficient than initially believed, the energy budget was adjusted: 70% for dendrites, 15% for axons, and 7% for astrocytes.[12] Previous accounts assumed that astrocytes captured synaptic K⁺ solely via Kir4.1 channels. However, it's now understood they also utilize Na⁺/K⁺ ATPase. Factoring in this active buffering, astrocytic energy demand increases by >200%. This is supported by 3D neuropil reconstructions indicating similar mitochondrial densities in both cell types, as well as cell-specific transcriptomic and proteomic data, and tricarboxylic acid cycle rates.[13] Therefore "Gram-per-gram, astrocytes turn out to be as expensive as neurons".[13]

Development

[edit]
Astrocytes are depicted in red. Cell nuclei are depicted in blue. Astrocytes were obtained from brains of newborn mice.

Astrocytes are macroglial cells in the central nervous system. Astrocytes are derived from heterogeneous populations of progenitor cells in the neuroepithelium of the developing central nervous system. There is remarkable similarity between the well known genetic mechanisms that specify the lineage of diverse neuron subtypes and that of macroglial cells.[14] Just as with neuronal cell specification, canonical signaling factors like sonic hedgehog (SHH), fibroblast growth factor (FGFs), WNTs and bone morphogenetic proteins (BMPs), provide positional information to developing macroglial cells through morphogen gradients along the dorsal–ventral, anterior–posterior and medial–lateral axes. The resultant patterning along the neuraxis leads to segmentation of the neuroepithelium into progenitor domains (p0, p1 p2, p3 and pMN) for distinct neuron types in the developing spinal cord. On the basis of several studies it is now believed that this model also applies to macroglial cell specification. Studies carried out by Hochstim and colleagues have demonstrated that three distinct populations of astrocytes arise from the p1, p2 and p3 domains.[15] These subtypes of astrocytes can be identified on the basis of their expression of different transcription factors (PAX6, NKX6.1) and cell surface markers (reelin and SLIT1). The three populations of astrocyte subtypes which have been identified are: 1) dorsally located VA1 astrocytes, derived from p1 domain, express PAX6 and reelin; 2) ventrally located VA3 astrocytes, derived from p3, express NKX6.1 and SLIT1; and 3) intermediate white-matter located VA2 astrocyte, derived from the p2 domain, which express PAX6, NKX6.1, reelin and SLIT1.[16] After astrocyte specification has occurred in the developing CNS, it is believed that astrocyte precursors migrate to their final positions within the nervous system before the process of terminal differentiation occurs.

Function

[edit]
Metabolic interactions between astrocytes and neurons[17]

Astrocytes help form the physical structure of the brain, and are thought to play a number of active roles, including the secretion or absorption of neural transmitters and maintenance of the blood–brain barrier.[18] The concept of a tripartite synapse has been proposed, referring to the tight relationship occurring at synapses among a presynaptic element, a postsynaptic element, and a glial element.[19]

Astrocyte endfeet processes surrounding a blood vessel
  • Structural: They are involved in the physical structuring of the brain. Astrocytes get their name because they are star-shaped. They are the most abundant glial cells in the brain that are closely associated with neuronal synapses. They regulate the transmission of electrical impulses within the brain.
  • Glycogen fuel reserve buffer: Astrocytes contain glycogen and are capable of gluconeogenesis. The astrocytes next to neurons in the frontal cortex and hippocampus store and release glucose. Thus, astrocytes can fuel neurons with glucose during periods of high rate of glucose consumption and glucose shortage. A recent research on rats suggests there may be a connection between this activity and physical exercise.[20]
  • Metabolic support: They provide neurons with nutrients such as lactate.
  • Glucose sensing: normally associated with neurons, the detection of interstitial glucose levels within the brain is also controlled by astrocytes. Astrocytes in vitro become activated by low glucose and are in vivo this activation increases gastric emptying to increase digestion.[21]
  • Blood–brain barrier: The astrocyte endfeet processes encircling endothelial cells were thought to aid in the maintenance of the blood–brain barrier, and recent research indicates that they do play a substantial role, along with the tight junctions and basal lamina.[citation needed] However, it has recently been shown that astrocyte activity is linked to blood flow in the brain, and that this is what is actually being measured in fMRI.[22][23]
  • Transmitter uptake and release: Astrocytes express plasma membrane transporters for several neurotransmitters, including glutamate, ATP, and GABA. More recently, astrocytes were shown to release glutamate or ATP in a vesicular, Ca2+-dependent manner.[24] (This has been disputed for hippocampal astrocytes.)[25]
  • Regulation of ion concentration in the extracellular space: Astrocytes express potassium channels at a high density. When neurons are active, they release potassium, increasing the local extracellular concentration. Because astrocytes are highly permeable to potassium, they rapidly clear the excess accumulation in the extracellular space.[26] If this function is interfered with, the extracellular concentration of potassium will rise, leading to neuronal depolarization by the Goldman equation. Abnormal accumulation of extracellular potassium is well known to result in epileptic neuronal activity.[27]
  • Modulation of synaptic transmission: In the supraoptic nucleus of the hypothalamus, rapid changes in astrocyte morphology have been shown to affect heterosynaptic transmission between neurons.[28] In the hippocampus, astrocytes suppress synaptic transmission by releasing ATP, which is hydrolyzed by ectonucleotidases to yield adenosine. Adenosine acts on neuronal adenosine receptors to inhibit synaptic transmission, thereby increasing the dynamic range available for LTP.[29]
  • Vasomodulation: Astrocytes may serve as intermediaries in neuronal regulation of blood flow.[30]
  • Promotion of the myelinating activity of oligodendrocytes: Electrical activity in neurons causes them to release ATP, which serves as an important stimulus for myelin to form. However, the ATP does not act directly on oligodendrocytes. Instead, it causes astrocytes to secrete cytokine leukemia inhibitory factor (LIF), a regulatory protein that promotes the myelinating activity of oligodendrocytes. This suggests that astrocytes have an executive-coordinating role in the brain.[31]
  • Nervous system repair: Upon injury to nerve cells within the central nervous system, astrocytes fill up the space to form a glial scar, and may contribute to neural repair. The role of astrocytes in CNS regeneration following injury is not well understood though. The glial scar has traditionally been described as an impermeable barrier to regeneration, thus implicating a negative role in axon regeneration. However, recently, it was found through genetic ablation studies that astrocytes are actually required for regeneration to occur.[32] More importantly, the authors found that the astrocyte scar is actually essential for stimulated axons (that axons that have been coaxed to grow via neurotrophic supplementation) to extend through the injured spinal cord.[32] Astrocytes that have been pushed into a reactive phenotype (termed astrogliosis, defined by the upregulation of among others, GFAP and vimentin[33] expression, a definition still under debate) may actually be toxic to neurons, releasing signals that can kill neurons.[34] Much work, however, remains to elucidate their role in nervous system injury.
  • Long-term potentiation: There is debate among scientists as to whether astrocytes integrate learning and memory in the hippocampus. Recently, it has been shown that engrafting human glial progenitor cell in nascent mice brains causes the cells to differentiate into astrocytes. After differentiation, these cells increase LTP and improve memory performance in the mice.[35]
  • Circadian clock: Astrocytes alone are sufficient to drive the molecular oscillations in the SCN and circadian behavior in mice, and thus can autonomously initiate and sustain complex mammalian behavior.[36]
  • The switch of the nervous system: Based on the evidence listed below, it has been recently conjectured in,[37] that macro glia (and astrocytes in particular) act both as a lossy neurotransmitter capacitor and as the logical switch of the nervous system. I.e., macroglia either block or enable the propagation of the stimulus along the nervous system, depending on their membrane state and the level of the stimulus.
Fig. 6 The conjectured switching role of glia in the biological neural detection scheme as suggested by Nossenson et al.[37][38]
Evidence supporting the switch and lossy capacitor role of glia as suggested in[37][38]
Evidence type Description References
Calcium evidence Calcium waves appear only if a certain concentration of neurotransmitter is exceeded [39][40][41]
Electrophysiological evidence A negative wave appears when the stimulus level crosses a certain threshold. The shape of the electrophysiological response is different and has the opposite polarity compared to the characteristic neural response, suggesting that cells other than neurons might be involved. [42][43]

[44] [45]

Psychophysical evidence The negative electrophysiological response is accompanied with all-or-none actions. A moderate negative electrophysiological response appears in conscious logical decisions such as perception tasks. An intense sharp negative wave appear in epileptic seizures and during reflexes. [42][45][43][44]
Radioactivity based glutamate uptake tests Glutamate uptake tests indicate that astrocyte process glutamate in a rate which is initially proportional to glutamate concentration. This supports the leaky capacitor model, where the 'leak' is glutamate processing by glia's glutamine synthetase. Furthermore, the same tests indicate on a saturation level after which neurotransmitter uptake level stops rising proportionally to neurotransmitter concentration. The latter supports the existence of a threshold. The graphs which show these characteristics are referred to as Michaelis-Menten graphs [46]

Astrocytes are linked by gap junctions, creating an electrically coupled (functional) syncytium.[47] Because of this ability of astrocytes to communicate with their neighbors, changes in the activity of one astrocyte can have repercussions on the activities of others that are quite distant from the original astrocyte.

An influx of Ca2+ ions into astrocytes is the essential change that ultimately generates calcium waves. Because this influx is directly caused by an increase in blood flow to the brain, calcium waves are said to be a kind of hemodynamic response function. An increase in intracellular calcium concentration can propagate outwards through this functional syncytium. Mechanisms of calcium wave propagation include diffusion of calcium ions and IP3 through gap junctions and extracellular ATP signalling.[48] Calcium elevations are the primary known axis of activation in astrocytes, and are necessary and sufficient for some types of astrocytic glutamate release.[49] Given the importance of calcium signaling in astrocytes, tight regulatory mechanisms for the progression of the spatio-temporal calcium signaling have been developed. Via mathematical analysis it has been shown that localized inflow of Ca2+ ions yields a localized raise in the cytosolic concentration of Ca2+ ions.[50] Moreover, cytosolic Ca2+ accumulation is independent of every intracellular calcium flux and depends on the Ca2+ exchange across the membrane, cytosolic calcium diffusion, geometry of the cell, extracellular calcium perturbation, and initial concentrations.[50]

Tripartite synapse

[edit]
Main article: Tripartite synapse

Within the dorsal horn of the spinal cord, activated astrocytes have the ability to respond to almost all neurotransmitters[51] and, upon activation, release a multitude of neuroactive molecules such as glutamate, ATP, nitric oxide (NO), and prostaglandins (PG), which in turn influences neuronal excitability. The close association between astrocytes and presynaptic and postsynaptic terminals as well as their ability to integrate synaptic activity and release neuromodulators has been termed the tripartite synapse.[19] Synaptic modulation by astrocytes takes place because of this three-part association.

A 2023 study suggested astrocytes, previously underexplored brain cells, could be key to extending wakefulness without negative effects on cognition and health.[52]

Glutamatergic gliotransmission

[edit]

Some specialized astrocytes mediate glutamatergic gliotransmission in the central nervous system.[53] Such cells have been called hybrid brain cells because they exhibit both neuron-like and glial-like properties. Unlike traditional neurons, these cells not only transmit electrical signals but also provide supportive roles typically associated with glial cells, such as regulating the brain's extracellular environment and maintaining overall homeostasis.[54][55][56]

Clinical significance

[edit]

Astrocytomas

[edit]

Astrocytomas are primary tumors in the CNS that develop from astrocytes. It is also possible that glial progenitors or neural stem cells can give rise to astrocytomas. These tumors may occur in many parts of the brain or spinal cord. Astrocytomas are divided into two categories: low grade (I and II) and high grade (III and IV). Low grade tumors are more common in children, and high grade tumors are more common in adults. Malignant astrocytomas are more prevalent among men, contributing to worse survival.[57]

Pilocytic astrocytomas are grade I tumors. They are considered benign and slow growing tumors. Pilocytic astrocytomas frequently have cystic portions filled with fluid and a nodule, which is the solid portion. Most are located in the cerebellum. Therefore, most symptoms are related to balance or coordination difficulties.[57] They also occur more frequently in children and teens.[58]

Fibrillary astrocytomas are grade II tumors. They grow relatively slowly so are usually considered benign, but they infiltrate the surrounding healthy tissue and can become malignant. Fibrillary astrocytomas commonly occur in younger people, who often present with seizures.[58]

Anaplastic astrocytomas are grade III malignant tumors. They grow more rapidly than lower grade tumors. Anaplastic astrocytomas recur more frequently than lower grade tumors because their tendency to spread into surrounding tissue makes them difficult to completely remove surgically.[57]

Glioblastoma is a grade IV cancer that may originate from astrocytes or an existing astrocytoma. Approximately 50% of all brain tumors are glioblastomas. Glioblastomas can contain multiple glial cell types, including astrocytes and oligodendrocytes. Glioblastomas are generally considered to be the most invasive type of glial tumor, as they grow rapidly and spread to nearby tissue. Treatment may be complicated, because one tumor cell type may die off in response to a particular treatment while the other cell types may continue to multiply.[57]

Neurodevelopmental disorders

[edit]

Astrocytes have emerged as important participants in various neurodevelopmental disorders. This view states that astrocyte dysfunction may result in improper neural circuitry, which underlies certain psychiatric disorders such as autism spectrum disorders and schizophrenia.[59][5]

Chronic pain

[edit]

Under normal conditions, pain conduction begins with some noxious signal followed by an action potential carried by nociceptive (pain sensing) afferent neurons, which elicit excitatory postsynaptic potentials (EPSP) in the dorsal horn of the spinal cord. That message is then relayed to the cerebral cortex, where we translate those EPSPs into "pain". Since the discovery of astrocyte-neuron signaling, our understanding of the conduction of pain has been dramatically complicated. Pain processing is no longer seen as a repetitive relay of signals from body to brain, but as a complex system that can be up- and down-regulated by a number of different factors. One factor at the forefront of recent research is in the pain-potentiating synapse located in the dorsal horn of the spinal cord and the role of astrocytes in encapsulating these synapses. Garrison and co-workers[60] were the first to suggest association when they found a correlation between astrocyte hypertrophy in the dorsal horn of the spinal cord and hypersensitivity to pain after peripheral nerve injury, typically considered an indicator of glial activation after injury. Astrocytes detect neuronal activity and can release chemical transmitters, which in turn control synaptic activity.[51][61][62] In the past, hyperalgesia was thought to be modulated by the release of substance P and excitatory amino acids (EAA), such as glutamate, from the presynaptic afferent nerve terminals in the spinal cord dorsal horn. Subsequent activation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-aspartate) and kainate subtypes of ionotropic glutamate receptors follows. It is the activation of these receptors that potentiates the pain signal up the spinal cord. This idea, although true, is an oversimplification of pain transduction. A litany of other neurotransmitter and neuromodulators, such as calcitonin gene-related peptide (CGRP), adenosine triphosphate (ATP), brain-derived neurotrophic factor (BDNF), somatostatin, vasoactive intestinal peptide (VIP), galanin, and vasopressin are all synthesized and released in response to noxious stimuli. In addition to each of these regulatory factors, several other interactions between pain-transmitting neurons and other neurons in the dorsal horn have added impact on pain pathways.

Two states of persistent pain

[edit]

After persistent peripheral tissue damage there is a release of several factors from the injured tissue as well as in the spinal dorsal horn. These factors increase the responsiveness of the dorsal horn pain-projection neurons to ensuing stimuli, termed "spinal sensitization", thus amplifying the pain impulse to the brain. Release of glutamate, substance P, and calcitonin gene-related peptide (CGRP) mediates NMDAR activation (originally silent because it is plugged by Mg2+), thus aiding in depolarization of the postsynaptic pain-transmitting neurons (PTN). In addition, activation of IP3 signaling and MAPKs (mitogen-activated protein kinases) such as ERK and JNK, bring about an increase in the synthesis of inflammatory factors that alter glutamate transporter function. ERK also further activates AMPARs and NMDARs in neurons. Nociception is further sensitized by the association of ATP and substance P with their respective receptors (P2X3) and neurokinin 1 receptor (NK1R), as well as activation of metabotropic glutamate receptors and release of BDNF. Persistent presence of glutamate in the synapse eventually results in dysregulation of GLT1 and GLAST, crucial transporters of glutamate into astrocytes. Ongoing excitation can also induce ERK and JNK activation, resulting in release of several inflammatory factors.

As noxious pain is sustained, spinal sensitization creates transcriptional changes in the neurons of the dorsal horn that lead to altered function for extended periods. Mobilization of Ca2+ from internal stores results from persistent synaptic activity and leads to the release of glutamate, ATP, tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-6, nitric oxide (NO), and prostaglandin E2 (PGE2). Activated astrocytes are also a source of matrix metalloproteinase 2 (MMP2), which induces pro-IL-1β cleavage and sustains astrocyte activation. In this chronic signaling pathway, p38 is activated as a result of IL-1β signaling, and there is a presence of chemokines that trigger their receptors to become active. In response to nerve damage, heat shock proteins (HSP) are released and can bind to their respective TLRs, leading to further activation.

Other pathologies

[edit]
See also: Neuroimmune system

Other clinically significant pathologies involving astrocytes include astrogliosis and astrocytopathy. Examples of these include multiple sclerosis, anti-AQP4+ neuromyelitis optica, Rasmussen's encephalitis, Alexander disease, and amyotrophic lateral sclerosis.[63] Studies have shown that astrocytes may be implied in neurodegenerative diseases, such as Alzheimer's disease,[64][65] Parkinson's disease,[66] Huntington's disease, Stuttering[67] and amyotrophic lateral sclerosis,[68] and in acute brain injuries, such as intracerebral hemorrhage [69] and traumatic brain injury.[70]

Gomori-positive astrocytes and brain dysfunction

[edit]

A type of astrocyte with an aging-related pathology has been described over the last fifty years. Astrocytes of this subtype possess prominent cytoplasmic granules that are intensely stained by Gomori's chrome alum hematoxylin stain, and hence are termed Gomori-positive (GP) astrocytes. They can be found throughout the brain, but are by far the most abundant in the olfactory bulbs, medial habenula, dentate gyrus of the hippocampus, arcuate nucleus of the hypothalamus, and in the dorsal medulla, just beneath the area postrema.[71]

Gomori-positive cytoplasmic granules are derived from damaged mitochondria engulfed within lysosomes.[72] Cytoplasmic granules contain undigested remnants of mitochondrial structures. These contents include heme-linked copper and iron atoms remaining from mitochondrial enzymes.[73] These chemical substances account for the pseudoperoxidase activity of Gomori-positive granules that can utilized to stain for these granules. Oxidative stress is believed to be cause of damage to these astrocytes.[74] However, the exact nature of this stress is uncertain.

Brain regions enriched in Gomori-positive astrocytes also contain a sub-population of specialized astrocytes that synthesize Fatty Acid Binding Protein 7 (FABP7). Indeed, astrocytes in the hypothalamus that synthesize FABP7 have also been shown to possess Gomori-positive granules.[75] Thus, a connection between these two glial features is apparent. Recent data have shown that astrocytes, but not neurons, possess the mitochondrial enzymes needed to metabolize fatty acids, and that the resulting oxidative stress can damage mitochondria.[76] Thus, an increased uptake and oxidation of fatty acids in glia containing FABP7 is likely to cause the oxidative stress and damage to mitochondria in these cells. Also, FABP proteins have recently been shown to interact with a protein called synuclein to cause mitochondrial damage.[77]

Possible roles in pathophysiology

[edit]

Astrocytes can transfer mitochondria into adjacent neurons to improve neuronal function.[78] It is therefore plausible that the damage to astrocyte mitochondria seen in GP astrocytes could affect the activity of neurons.

A number of hypothalamic functions show declines in aging that may be related to GP astrocytes. For example, GP astrocytes are in close contact with neurons that make a neurotransmitter called dopamine in both the rat and human hypothalamus.[79] The dopamine produced by these neurons is carried to the nearby pituitary gland to inhibit the release of a hormone called prolactin from the pituitary. The activity of dopaminergic neurons declines during aging, leading to elevations in blood levels of prolactin that can provoke breast cancer.[80] An aging-associated change in astrocyte function might contribute to this change in dopaminergic activity.

FABP7+ astrocytes are in close contact with neurons in the arcuate nucleus of the hypothalamus that are responsive to a hormone called leptin that is produced by fat cells. Leptin-sensitive neurons regulate appetite and body weight. FABP7+ astrocytes regulate the responsiveness of these neurons to leptin. Mitochondrial damage in these astrocytes could thus alter the function of leptin-sensitive neurons and could contribute to an aging-associated dysregulation of feeding and body weight.[81]

GP astrocytes may also be involved in the hypothalamic regulation of overall glucose metabolism. Recent data show that astrocytes function as glucose sensors and exert a commanding influence upon neuronal reactivity to changes in extracellular glucose.[82] GP astrocytes possess high-capacity GLUT2-type glucose transporter proteins and appear to modulate the neuronal responses to glucose.[83] Hypothalamic cells monitor blood levels of glucose and exert an influence upon blood glucose levels via an altered input to autonomic circuits that innervate liver and muscle cells.

The importance of astrocytes in aging-related disturbances in glucose metabolism has been recently illustrated by studies of diabetic animals. A single infusion of a protein called fibroblast growth factor-1 into the hypothalamus has been shown to permanently normalize blood glucose levels in diabetic rodents. This remarkable cure of diabetes mellitus is mediated by astrocytes. The most prominent genes activated by FGF-1 treatment include the genes responsible for the synthesis of FABP6 and FABP7 by astrocytes.[84] These data confirm the importance of FABP7+ astrocytes for the control of blood glucose. Dysfunction of FABP7+/Gomori-positive astrocytes may contribute to the aging-related development of diabetes mellitus.

GP astrocytes are also present in the dentate gyrus of the hippocampus in both rodent and human brains.[85] The hippocampus undergoes severe degenerative changes during aging in Alzheimer's disease. The reasons for these degenerative changes are currently being hotly debated. A recent study has shown that levels of glial proteins, and NOT neuronal proteins, are most abnormal in Alzheimer's disease. The glial protein most severely affected is FABP5.[86] Another study showed that 100% of hippocampal astrocytes that contain FABP7 also contain FABP5.[87] These data suggest that FABP7+/Gomori-positive astrocytes may play a role in Alzheimer's disease. An altered glial function in this region could compromise the function of dentate gyrus neurons and also the function of axons that terminate in the dentate gyrus. Many such axons originate in the lateral entorhinal cortex, which is the first brain region to show degeneration in Alzheimer's disease. Astrocyte pathology in the hippocampus thus might make a contribution to the pathology of Alzheimer's disease.

Research

[edit]

A study performed in November 2010 and published March 2011, was done by a team of scientists from the University of Rochester and University of Colorado School of Medicine. They did an experiment to attempt to repair trauma to the Central Nervous System of an adult rat by replacing the glial cells. When the glial cells were injected into the injury of the adult rat's spinal cord, astrocytes were generated by exposing human glial precursor cells to bone morphogenetic protein (bone morphogenetic protein is important because it is considered to create tissue architecture throughout the body). So, with the bone protein and human glial cells combined, they promoted significant recovery of conscious foot placement, axonal growth, and obvious increases in neuronal survival in the spinal cord laminae. On the other hand, human glial precursor cells and astrocytes generated from these cells by being in contact with ciliary neurotrophic factors, failed to promote neuronal survival and support of axonal growth at the spot of the injury.[88]

One study done in Shanghai had two types of hippocampal neuronal cultures: In one culture, the neuron was grown from a layer of astrocytes and the other culture was not in contact with any astrocytes, but they were instead fed a glial conditioned medium (GCM), which inhibits the rapid growth of cultured astrocytes in the brains of rats in most cases. In their results they were able to see that astrocytes had a direct role in Long-term potentiation with the mixed culture (which is the culture that was grown from a layer of astrocytes) but not in GCM cultures.[89]

Studies have shown that astrocytes play an important function in the regulation of neural stem cells. Research from the Schepens Eye Research Institute at Harvard shows the human brain to abound in neural stem cells, which are kept in a dormant state by chemical signals (ephrin-A2 and ephrin-A3) from the astrocytes. The astrocytes are able to activate the stem cells to transform into working neurons by dampening the release of ephrin-A2 and ephrin-A3.[90]

In a study published in a 2011 issue of Nature Biotechnology[91] a group of researchers from the University of Wisconsin reports that it has been able to direct embryonic and induced human stem cells to become astrocytes.

A 2012 study[92] of the effects of marijuana on short-term memories found that THC activates CB1 receptors of astrocytes which cause receptors for AMPA to be removed from the membranes of associated neurons.

A 2023 study[93] showed that astrocytes also play an active role in Alzheimer's disease. More specifically, when astrocytes became reactive they unleash the pathological effects of amyloid-beta on downstream tau phosphorylation and deposition, which very likely will lead to cognitive deterioration.

Classification

[edit]

There are several different ways to classify astrocytes.

Lineage and antigenic phenotype

[edit]

These have been established by classic work by Raff et al. in early 1980s on Rat optic nerves.

  • Type 1: Antigenically Ran2+, GFAP+, FGFR3+, A2B5−, thus resembling the "type 1 astrocyte" of the postnatal day 7 rat optic nerve. These can arise from the tripotential glial restricted precursor cells (GRP), but not from the bipotential O2A/OPC (oligodendrocyte, type 2 astrocyte precursor, also called Oligodendrocyte progenitor cell) cells.
  • Type 2: Antigenically A2B5+, GFAP+, FGFR3−, Ran 2−. These cells can develop in vitro from the either tripotential GRP (probably via O2A stage) or from bipotential O2A cells (which some people{{[94]}} think may in turn have been derived from the GRP) or in vivo when these progenitor cells are transplanted into lesion sites (but probably not in normal development, at least not in the rat optic nerve). Type 2 astrocytes are the major astrocytic component in postnatal optic nerve cultures that are generated by O2A cells grown in the presence of fetal calf serum but are not thought to exist in vivo.[95]

Anatomical classification

[edit]
  • Protoplasmic: found in grey matter and have many branching processes whose end-feet envelop synapses. Some protoplasmic astrocytes are generated by multipotent subventricular zone progenitor cells.[96][97]
  • Gömöri-positive astrocytes. These are a subset of protoplasmic astrocytes that contain numerous cytoplasmic inclusions, or granules, that stain positively with Gömöri trichrome stain a chrome-alum hematoxylin stain. It is now known that these granules are formed from the remnants of degenerating mitochondria engulfed within lysosomes,[98] Some type of oxidative stress appears to be responsible for the mitochondrial damage within these specialized astrocytes. Gömöri-positive astrocytes are much more abundant within the arcuate nucleus of the hypothalamus and in the hippocampus than in other brain regions. They may have a role in regulating the response of the hypothalamus to glucose.[99][100]
  • Fibrous: found in white matter and have long thin unbranched processes whose end-feet envelop nodes of Ranvier. Some fibrous astrocytes are generated by radial glia.[101][102][103][104][105]

Transporter/receptor classification

[edit]
  • GluT type: these express glutamate transporters (EAAT1/SLC1A3 and EAAT2/SLC1A2) and respond to synaptic release of glutamate by transporter currents. The function and availability of EAAT2 is modulated by TAAR1, an intracellular receptor in human astrocytes.[106]
  • GluR type: these express glutamate receptors (mostly mGluR and AMPA type) and respond to synaptic release of glutamate by channel-mediated currents and IP3-dependent Ca2+ transients.

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Astrocyte

View on Grokipedia
from Grokipedia
Astrocytes are star-shaped glial cells that constitute a major component of the central nervous system (CNS), comprising approximately 20-40% of all brain cells (astrocyte-to-neuron ratio ∼0.7:1 in the cerebral cortex)[1] and occupying 25-50% of the brain's volume.[2] Named after their characteristic morphology by Mihaly von Lenhossek in 1895, these ectodermal-derived cells form non-overlapping domains that tile the entire CNS, providing essential structural and metabolic support to neurons while actively participating in information processing.[2] In healthy brains, astrocytes maintain homeostasis by regulating ion balance, pH, and neurotransmitter levels, and they form tripartite synapses with pre- and postsynaptic neuronal elements, influencing synaptic plasticity and transmission.[3] Morphologically, astrocytes exhibit diverse subtypes, including protoplasmic astrocytes in gray matter with bushy, highly branched processes that envelop synapses and blood vessels, and fibrous astrocytes in white matter with elongated, less ramified extensions aligned along axonal tracts.[2] A single protoplasmic astrocyte can contact hundreds of neuronal dendrites and up to 100,000 synapses in rodents or over 2 million in humans, facilitated by fine perisynaptic processes (PAPs) that contain calcium signaling machinery and enable dynamic interactions.[3] These cells express glial fibrillary acidic protein (GFAP) as a key cytoskeletal marker, though GFAP-negative populations highlight their heterogeneity across brain regions.[4] Astrocytes are interconnected via gap junctions, allowing synchronized calcium waves and coordinated responses across networks.[4] Functionally, astrocytes support neuronal activity through multiple mechanisms, including the uptake and recycling of neurotransmitters like glutamate via transporters such as GLT-1, which prevents excitotoxicity and shapes synaptic signaling.[3] They store glycogen as an energy reserve, releasing lactate and other metabolites to fuel neurons during high-demand periods or hypoglycemia, thus linking neuronal metabolism to cerebral blood flow regulation.[4] Beyond support, astrocytes exhibit gliotransmission by releasing signaling molecules like glutamate, ATP, and D-serine in response to calcium transients, modulating synaptic strength and contributing to processes such as long-term potentiation (LTP).[3] Their processes also form endfeet that maintain the blood-brain barrier (BBB) integrity, provide neurotrophic factors, and detoxify reactive oxygen species, underscoring their role in CNS defense and repair.[2] In addition to static functions, astrocytes display structural plasticity, with PAPs extending or retracting in response to sensory stimuli, learning, or circadian rhythms, thereby fine-tuning neural circuits and behaviors like memory formation.[3] This adaptability positions astrocytes as active partners in brain dynamics, with disruptions linked to neurological disorders, though their precise contributions in pathology remain under investigation.[2]

Structure and Morphology

General Morphology

Astrocytes are star-shaped glial cells distinguished by a central cell body, or soma, from which numerous primary processes radiate outward, creating a stellate morphology that facilitates extensive interactions within the central nervous system.[5] These processes branch into finer secondary and tertiary extensions, allowing astrocytes to form a supportive network around neurons and vasculature.[2] The overall structure enables astrocytes to occupy non-overlapping territorial domains in the brain parenchyma, with each astrocyte typically spanning tens to hundreds of micrometers depending on species and region.[4] Key cellular components of astrocytes include a prominent, euchromatic nucleus within the soma, indicative of high transcriptional activity, surrounded by cytoplasm containing mitochondria, endoplasmic reticulum, and other organelles essential for metabolic support.[4] The cytoskeleton is reinforced by intermediate filaments, notably glial fibrillary acidic protein (GFAP), which provides mechanical stability to the processes and serves as a hallmark marker for astrocyte identification.[5] Intercellular communication occurs through gap junctions composed of connexin proteins, such as connexin 43 (Cx43), which couple adjacent astrocytes into functional syncytia.[2] Astrocytes exhibit specialized domain organization, with perisynaptic processes that envelop neuronal synapses—often wrapping up to 60-90% of synaptic surfaces in certain brain regions—and vascular endfeet that form tight sheaths around capillaries.[5] These endfeet cover approximately 99% of the cerebral vascular surface, integrating astrocytes into the neurovascular unit.[6] This arrangement positions astrocytes at the interface of the tripartite synapse, where they interact with pre- and postsynaptic elements.[4] Historically, these cells were first described by Otto Deiters in 1865 as connective tissue elements with a central nucleus and radiating fiber tracts, based on his microscopic examinations of mammalian brain tissue.[7]

Protoplasmic Astrocytes

Protoplasmic astrocytes are primarily located in the gray matter of the cerebral and cerebellar cortices, where they form a key component of the neuropil.[8][9] These cells exhibit a highly branched morphology characterized by numerous short, velate processes that emanate from the soma, creating a spongy, sponge-like network that tiles non-overlapping territories within the tissue.[8][9] This intricate arborization allows individual protoplasmic astrocytes to occupy distinct domains, interacting with neighboring astrocytes only at their peripheral edges to ensure comprehensive coverage of the local environment.[10] A distinguishing feature of protoplasmic astrocytes is their extensive association with synapses, with each cell capable of ensheathing up to 100,000 synaptic contacts in rodents.[3] These processes often form leaf-like expansions that closely appose neuronal elements, including dendritic spines and axon terminals, facilitating intimate structural interactions at glutamatergic and GABAergic synapses throughout the gray matter.[11] In contrast to fibrous astrocytes, which predominate in white matter tracts and exhibit straighter processes aligned with myelinated fibers, protoplasmic astrocytes display lower levels of glial fibrillary acidic protein (GFAP) expression, reflecting their adapted morphology for synaptic proximity rather than axonal support.[12][13]

Fibrous Astrocytes

Fibrous astrocytes are primarily located in white matter regions of the central nervous system, such as the corpus callosum, optic tract, and internal capsule, where they align with myelinated axonal tracts.[14][15] These cells exhibit an elongated morphology characterized by a central cell body from which extend fewer but longer processes compared to protoplasmic astrocytes, with reduced branching complexity suited to the linear organization of white matter.[16] Their processes are rich in intermediate filaments, particularly glial fibrillary acidic protein (GFAP), which is highly expressed and serves as a key immunohistochemical marker for identifying these cells.[4][14] The fibrous processes of these astrocytes form dense bundles that run parallel to myelinated axons, providing structural support and facilitating ion homeostasis along white matter pathways.[4] These processes often terminate at or contact nodes of Ranvier, the gaps between myelin sheaths where action potentials are generated, thereby contributing to the maintenance of axonal integrity and saltatory conduction.[16][14] In terms of spatial organization, fibrous astrocytes display less territorial exclusivity than their gray matter counterparts, with processes showing considerable overlap among neighboring cells, which allows for coordinated coverage of extensive white matter volumes.[14] Quantitatively, individual fibrous astrocytes in human white matter can span larger domains, with processes extending up to 100-200 μm in length and each cell reflecting their adaptation to the sparser cellular density of white matter (approximately 79 cells/mm² in the corpus callosum).[17][14] This extended reach enables them to interact with multiple axons over greater distances, underscoring their role in supporting the efficiency of long-range neural signaling.[18]

Radial Glia

Radial glia represent a transient subtype of astrocytes that serve as scaffold-like cells during embryonic brain development, characterized by their elongated morphology and strategic positioning within the neural tube. These cells are distributed throughout the embryonic neural tube, with their somata primarily located in the ventricular zone and extending processes that span from the ventricular surface to the pial surface, thereby bridging the developing cortical layers.[19][20] The defining morphology of radial glia includes long radial processes that can extend up to 1 mm or more in length, forming a palisade-like arrangement that provides structural support across the neural epithelium. These processes originate from the ovoid cell body near the ventricular zone, featuring a short apical process terminating in an endfoot at the ventricle and a longer basal process that reaches the pial surface, often branching into multiple endfeet for attachment.[21][22][23] Radial glia express specific markers that reflect their developmental stage, such as vimentin in early phases, which transitions to glial fibrillary acidic protein (GFAP) expression as neurogenesis progresses. Their somata reside in the ventricular zone, and their radial processes facilitate the guidance of neuronal migration during corticogenesis.[19][24] Following the completion of neurogenesis, many radial glia differentiate into mature astrocytes in the postnatal period, while some retain radial-like features in specific adult regions, such as Bergmann glia in the cerebellum.[25]

Classification

Lineage and Antigenic Markers

Astrocytes primarily derive from neuroepithelial progenitors located in the embryonic ventricular zone, which transition into radial glia cells that serve as intermediate progenitors for both neurons and glia.[26] These radial glia cells generate the majority of cortical astrocytes through asymmetric divisions, particularly during late neurogenesis when they switch from producing neurons to glial cells.[27] Additionally, a subset of astrocytes arises from progenitors in the subventricular zone, including bipotent precursors that can differentiate into both astrocytes and oligodendrocytes.[28] Key antigenic markers facilitate the identification and classification of astrocytes based on their protein expression profiles. Glial fibrillary acidic protein (GFAP), an intermediate filament protein, is a widely used marker that becomes upregulated during astrocyte maturation and is particularly prominent in reactive states.[29] Aldehyde dehydrogenase 1 family member L1 (ALDH1L1) serves as a pan-astrocyte marker, expressed in nearly all mature astrocytes regardless of subtype or region, making it highly selective for astrocyte identification.[30] S100B, a calcium-binding protein, is another common marker that highlights astrocyte cell bodies and is often used in conjunction with GFAP and ALDH1L1 for comprehensive labeling.[31] Antigenic phenotypes distinguish astrocyte subtypes, with Type I astrocytes originating from radial glia and exhibiting a protoplasmic or fibrous morphology, characterized by GFAP positivity and absence of A2B5 expression.[32] Regional variations in these phenotypes are evident, such as higher GFAP expression in white matter astrocytes compared to gray matter protoplasmic types, reflecting adaptations to local tissue demands.[12] Note that distinctions like A2B5 expression are more prominent in developmental or in vitro contexts, while in vivo classifications increasingly rely on transcriptomic profiles. The use of GFAP as an astrocyte marker originated in the 1970s, when it was isolated from multiple sclerosis plaques and recognized as a specific indicator of astroglial cells, revolutionizing neuropathological diagnostics.[33] Advances in single-cell RNA sequencing during the 2020s have further illuminated astrocyte heterogeneity, revealing diverse transcriptional states and subtypes beyond traditional markers, including region-specific clusters with varying progenitor origins and functional specializations such as disease-associated reactive states.[34][35]

Anatomical Features

Astrocytes are classified anatomically based on their location within the brain's gray and white matter. Protoplasmic astrocytes, characterized by their bushy processes, predominate in gray matter regions, where they form intimate associations with synaptic domains.[18] In contrast, fibrous astrocytes, with their elongated, less branched processes, are primarily located in white matter, aligning closely with bundles of myelinated axons.[36] This positional distinction reflects adaptations to the distinct structural demands of neuronal elements in these compartments.[37] A key anatomical feature of astrocytes is their territorial organization, in which individual cells establish non-overlapping domains that tile the brain parenchyma. These domains allow each astrocyte to cover a specific volume, with processes from neighboring cells rarely overlapping, ensuring efficient partitioning of neural space.[38] For example, in cortical regions, a single astrocyte's territory typically encompasses thousands to hundreds of thousands of synapses belonging to hundreds (e.g., 300-600) of neuronal processes.[39][40] Collectively, the processes of astrocytes occupy approximately 20-40% of the brain's volume, contributing substantially to the neuropil's architecture.[8] Regional variations in astrocyte anatomy further highlight their positional diversity. In the cerebellum, Bergmann glia represent a specialized radial subtype, extending pial-directed processes that provide structural support to Purkinje cells and guide granule cell migration.[41] Similarly, in the retina, Müller glia function as elongated radial astrocytes that span all retinal layers, from the inner limiting membrane to the outer limiting membrane, maintaining retinal lamination and homeostasis.[42] Quantitative assessments of astrocyte distribution reveal species-specific differences in density and ratios. In the cerebral cortex, the astrocyte-to-neuron ratio is approximately 1:1, though this varies by region and species.[43] In humans, this ratio is approximately 1:1.4, higher than the roughly 1:3 ratio observed in rodent brains, reflecting an evolutionary expansion of astrocyte populations documented in studies from the 2010s.[43][44] This increase underscores the scaling of glial support with neuronal complexity in larger brains.[1]

Molecular Transporters and Receptors

Astrocytes express a diverse array of molecular transporters and receptors that underpin their involvement in neuronal signaling and brain homeostasis. Key ion transporters include the excitatory amino acid transporters EAAT1 (also known as GLAST) and EAAT2 (GLT-1), which are predominantly localized to astrocytic membranes surrounding synapses and mediate the rapid uptake of glutamate to regulate extracellular levels.[45] Inwardly rectifying potassium (Kir) channels, particularly the Kir4.1 subtype, are enriched in astrocyte processes and perisynaptic regions, facilitating the spatial buffering of potassium ions to maintain extracellular ion balance during synaptic activity.[46][47] Neurotransmitter receptors on astrocytes enable detection of synaptic signals and reciprocal communication. Metabotropic glutamate receptors (mGluRs), such as group I subtypes (mGluR1 and mGluR5), are expressed in astrocytic membranes and respond to glutamate to mobilize intracellular calcium, supporting astrocyte-neuron interactions.[48][49] GABA receptors, including GABA_B subtypes, allow astrocytes to sense inhibitory neurotransmission and modulate their own excitability.[50] Purinergic receptors, notably P2Y1, detect extracellular ATP and trigger calcium-dependent responses that contribute to gliotransmission.[51][52] Transcriptomic analyses in the 2020s have highlighted astrocyte heterogeneity through differential expression of these molecules, enabling classification into subtypes with varying functional specializations; for example, some populations show high EAAT expression suited for synaptic glutamate clearance, while others exhibit lower levels potentially emphasizing metabolic roles.[53][10] This molecular diversity is further exemplified by aquaporin-4 (AQP4), a water channel protein concentrated in perivascular astrocyte endfeet to regulate water flux at the blood-brain interface.[54] Connexin 43 (Cx43), the dominant connexin isoform in astrocytes, forms gap junctions that couple cells into syncytia, permitting the passage of ions and metabolites for coordinated network responses.[55][56]

Development

Embryonic Origin

Astrocytes originate from neuroepithelial progenitor cells lining the neural tube during early embryogenesis. In mice, these progenitors emerge around embryonic day 8 (E8) to E10, initially undergoing symmetric divisions to expand the progenitor pool before transitioning to asymmetric divisions that generate neurons first and glia later.[57] This process is conserved across mammals, with human equivalents occurring during the first trimester, when the neural tube closes and differentiates into the central nervous system.[58] The switch from neurogenesis to gliogenesis is facilitated by the activation of Notch signaling, which inhibits neuronal differentiation and promotes glial fate commitment in these progenitors through the release of the Notch intracellular domain (NICD) and subsequent transcriptional regulation via RBPJ.[59] The onset of gliogenesis is tightly regulated by key transcription factors, including Sox9 and nuclear factor I-A/B (NFIA/B), which coordinate a regulatory cascade in rodent models. Sox9 is induced early, around E9.5–E11.5 in mice, where it directly activates NFIA expression via enhancer elements, marking the initiation of astrocyte precursor formation around E11.5–E12.5 in the spinal cord and extending to E12–E14 in the cortex.[60] NFIA, acting downstream and in complex with Sox9, drives the expression of glial-specific genes such as Gfap and cooperates to establish astroglial identity, ensuring the proper timing of this fate switch.[61] These factors are essential for transforming neuroepithelial-derived progenitors into committed glial cells. Astrocyte progenitors in the ventricular zone of the neural tube undergo regional specification influenced by morphogen gradients, such as Sonic hedgehog (Shh) and bone morphogenetic proteins (BMPs), which pattern distinct domains and direct subtype diversity. In the cortex, these progenitors give rise to parenchymal astrocytes, with gliogenesis initiating around E11.5 and continuing into later embryonic stages, while spinal cord astrocytes emerge earlier, patterned into ventral subtypes (e.g., VA1–VA3) by combinatorial transcription factors like Pax6 and Nkx6.1.[62] This spatiotemporal variation ensures region-specific astrocyte populations aligned with local neuronal circuits. In humans, gliogenesis extends significantly into the postnatal period compared to rodents, with substantial astrocyte generation occurring after birth through local proliferation of differentiated precursors, contributing to the expanded glial-to-neuronal ratio and larger brain size observed in the species.[63] This prolonged timeline, supported by studies from 2012 onward, allows for greater experience-dependent refinement of astrocytic networks.[64]

Differentiation and Maturation

Astrocyte precursors, primarily derived from radial glia through asymmetric division, undergo gliogenesis predominantly in the postnatal period. In rodents, this process peaks between postnatal day 0 (P0) and P10, with radial glia in the ventricular zone generating glioblasts that migrate and differentiate into astrocytes, contributing to the majority of the astrocyte population by P28.[65] In humans, astrocyte generation largely completes by gestational week 30–40, but maturation extends into the first two years postnatal, aligning with ongoing synaptogenesis and circuit refinement.[66] Key regulatory signals drive the expression of maturation markers such as glial fibrillary acidic protein (GFAP). Bone morphogenetic protein (BMP) signaling, via the Smad1/5/8 pathway, promotes morphological maturation and upregulates GFAP in immature astrocytes during early postnatal stages (P0–P7), while also limiting proliferation to favor differentiation.[67] Similarly, transforming growth factor-β (TGF-β) activates the GFAP promoter, enhancing its expression and supporting astrocyte reactivity and maturity.[68] Thyroid hormone (T3) influences maturation timing by facilitating the transition from fetal to adult astrocyte phenotypes, regulating gene expression, morphogenesis, and functional specialization in postnatal development.[69] Postnatal differentiation reveals emerging heterogeneity, with regional variations in maturation dynamics; for instance, cortical astrocytes proliferate and mature earlier than subcortical counterparts like those in the hypothalamus, where proliferation peaks later (P15–P30) and domain sizes remain smaller.[70] Hippocampal astrocytes exhibit delayed maturation compared to cortical ones, contributing to region-specific functional profiles.[71] Quantitatively, astrocyte numbers in the rodent cortex increase six- to eight-fold during the first three postnatal weeks, reflecting robust gliogenesis.[65] Recent studies highlight sex-specific differences, with male rodents showing accelerated maturation peaking at P7 and P14 due to perinatal testosterone effects on gene expression, while females display enhanced estradiol responsiveness influencing proliferation and neuroprotection.[72][73] Injury-induced reactive changes can accelerate this differentiation, promoting faster GFAP expression and process extension in precursors.[74]

Functions

Structural and Synaptic Support

Astrocytes provide essential structural support to the central nervous system by forming a scaffold that stabilizes neuronal elements, particularly at synapses. Their fine processes, known as perisynaptic astrocytic processes, ensheath synaptic structures, enveloping both pre- and postsynaptic components to maintain architectural integrity. This ensheathment helps stabilize dendritic spines, the postsynaptic sites of excitatory synapses, by promoting their maturation and preventing excessive motility during synaptic plasticity.[75] Additionally, astrocytes contribute to the maintenance of the extracellular matrix (ECM) surrounding synapses through the secretion of proteoglycans, such as chondroitin sulfate proteoglycans, which provide structural rigidity and modulate neuronal adhesion.[76] A key aspect of this structural role is the integration of astrocytes into the tripartite synapse, a functional unit comprising presynaptic terminals, postsynaptic densities, and astrocytic processes. This concept, formalized by Araque et al. in 1999, highlights how astrocytes actively participate in synaptic physiology by detecting neuronal activity through calcium signaling in their processes.[77] Each astrocyte can contact up to 100,000 synapses in rodents and over 2 million in humans, allowing a single cell to influence vast networks of synaptic interactions.[78] Astrocytic processes respond to synaptic activation by propagating calcium waves, which enable the cell to sense and modulate synaptic strength without directly altering neuronal firing. Astrocytes further support synaptic function through specific mechanisms that regulate the synaptic microenvironment. They facilitate perisynaptic uptake and trapping of neurotransmitters, such as glutamate, via transporters like EAAT1 and EAAT2 located on their processes, thereby preventing spillover and maintaining precise signaling.[79] Moreover, astrocytes contribute to extracellular volume regulation by buffering ions and osmolytes, which helps prevent synaptic edema and preserves the narrow extracellular spaces essential for efficient diffusion around synapses. This volume control is mediated by channels like aquaporin-4 and potassium channels, ensuring homeostasis during periods of heightened activity.[80]

Gliotransmission

Astrocytes engage in gliotransmission by releasing signaling molecules that actively modulate neuronal excitability and synaptic function within the tripartite synapse framework. This process involves the calcium-dependent exocytosis of gliotransmitters such as glutamate, ATP, and D-serine from vesicular compartments, enabling astrocytes to influence neuronal networks independently of direct synaptic input.[81][82] The primary mechanism of gliotransmitter release in astrocytes is calcium-dependent vesicular exocytosis, mediated by SNARE proteins that facilitate vesicle fusion with the plasma membrane. Seminal studies demonstrated that elevations in intracellular calcium trigger the release of glutamate from astrocytes, requiring SNARE complex formation involving proteins like VAMP2 and syntaxin-4.[83] Similar vesicular mechanisms apply to ATP and D-serine, where calcium influx promotes the docking and fusion of secretory vesicles containing these molecules.[84][85] While early evidence supported this exocytotic pathway, the 2010s literature debated the predominance of vesicular versus non-vesicular release routes, such as transporter reversal or channel-mediated efflux; however, high-resolution imaging and genetic studies have since affirmed calcium-triggered vesicular exocytosis as a key regulated process in intact brain tissue.[86][82] Glutamatergic gliotransmission exemplifies this process, as astrocytes release glutamate to activate neuronal NMDA receptors, thereby enhancing synaptic plasticity and long-term potentiation. This release occurs focally near synapses, allowing precise modulation of neuronal calcium influx and AMPA receptor trafficking without spillover artifacts.[82][87] For D-serine, astrocytes serve as a primary source, co-agonizing NMDA receptors to gate synaptic NMDA currents and support memory-related plasticity.[85] ATP release from astrocytes, often via pannexin-1 hemichannels or vesicles, undergoes ecto-enzymatic hydrolysis to adenosine, which binds A1 receptors on neurons to dampen excitability and provide negative feedback during prolonged activity.[84][88] Gliotransmission is tightly regulated by synaptic activity, particularly through metabotropic glutamate receptors (mGluRs) on astrocytes that detect glutamate spillover and initiate intracellular calcium waves. Activation of group I mGluRs, such as mGluR5, couples to phospholipase C, generating IP3 to release calcium from stores and trigger exocytosis.[89] This feedback loop ensures gliotransmitter release scales with neuronal firing rates, maintaining synaptic homeostasis.[81]

Metabolic and Energy Support

Astrocytes play a pivotal role in brain energy metabolism by serving as the primary site for glucose uptake and processing, which supports neuronal energy demands through the astrocyte-neuron lactate shuttle (ANLS). In this mechanism, glutamate released from active neurons is taken up by astrocytes via excitatory amino acid transporters, stimulating aerobic glycolysis within astrocytes despite sufficient oxygen availability. This process leads to the production of lactate from glucose, which is then exported to neurons for oxidation in mitochondria to generate ATP, coupling neuronal activity directly to energy substrate provision. The ANLS was first proposed by Pellerin and Magistretti in 1994 based on evidence showing that glutamate uptake increases glycolytic flux in astrocytes, with lactate serving as the preferred energy substrate for neurons under high activity conditions. Key to the ANLS is the compartmentalization of metabolic enzymes and transporters: astrocytes express high levels of lactate dehydrogenase isoform LDHA, favoring lactate production, and monocarboxylate transporters MCT1 and MCT4 for lactate export, while neurons express LDHB and MCT2 for efficient uptake and utilization. During periods of increased neural activity, this shuttle ensures rapid energy supply, as lactate can be oxidized more quickly than glucose in neurons. Astrocytes access glucose primarily through glucose transporter 1 (GLUT1) at the blood-brain barrier interface, facilitating the initial uptake step in this metabolic pathway.[90][91] Astrocytes also maintain brain energy reserves by storing the majority of cerebral glycogen, primarily in their processes. Glycogen in astrocytes acts as a dynamic buffer, mobilized during synaptic activity or energy deficits to replenish lactate via anaerobic glycolysis. The core reaction involves the breakdown of glycogen to glucose-1-phosphate, followed by glycolysis yielding lactate and net ATP production, as represented by the simplified equation for anaerobic glycolysis:
Glucose+2ADP+2Pi+2NAD+→2Lactate+2ATP+2NADH+2H+ \text{Glucose} + 2 \text{ADP} + 2 \text{P}_i + 2 \text{NAD}^+ \rightarrow 2 \text{Lactate} + 2 \text{ATP} + 2 \text{NADH} + 2 \text{H}^+
This process generates 2 ATP per glucose molecule under anaerobic conditions, supporting short-term energy needs when oxidative metabolism is limited. Astrocytic glycogenolysis is regulated by adrenergic and glutamatergic signaling, ensuring timely release of lactate to sustain neuronal function during arousal or ischemia.[92][93] Beyond carbohydrates, astrocytes contribute to lipid metabolism by synthesizing cholesterol and phospholipids essential for neuronal membrane maintenance and myelin formation. Astrocytes are the primary source of cholesterol in the central nervous system, exporting it via apolipoprotein E (apoE)-containing lipoproteins to oligodendrocytes and neurons, which lack the capacity for de novo cholesterol synthesis. This supports myelin sheath production, where phospholipids like phosphatidylcholine are also provided by astrocytes to oligodendrocytes during myelination. In states of fasting, astrocytes metabolize ketone bodies derived from peripheral lipolysis, converting them into energy substrates or further processing them for neuronal use, thereby adapting brain metabolism to glucose scarcity. Recent studies highlight astrocytes' ability to produce ketone bodies locally from fatty acids, fueling neurons and maintaining homeostasis during prolonged fasting.[94][95] Emerging research from 2022 to 2025 emphasizes the role of astrocyte mitochondrial dynamics in managing reactive oxygen species (ROS) during energy crises, such as hypoglycemia or ischemia. Mitochondrial fission and fusion, mediated by proteins like Drp1 and OPA1, allow astrocytes to adapt bioenergetics by segregating damaged mitochondria for mitophagy, thereby mitigating ROS-induced oxidative stress that could impair lactate production. This dynamic regulation preserves astrocyte metabolic support to neurons, with disruptions linked to impaired energy provisioning in metabolic stress. For instance, enhanced fission promotes ROS clearance, enabling sustained glycolysis and glycogen mobilization under low-energy conditions.[96][97]

Blood-Brain Barrier Maintenance

Astrocytes play a crucial role in the formation and maintenance of the blood-brain barrier (BBB) through their perivascular endfeet, which extensively cover the abluminal surface of brain capillaries and form the glia limitans vascularis, providing structural support and regulating endothelial permeability. These endfeet processes ensheath over 99% of the vascular surface in mature brains, facilitating direct communication with endothelial cells to induce and sustain barrier properties.[98] Astrocytes secrete signaling molecules such as vascular endothelial growth factor (VEGF) and sonic hedgehog (SHH), which promote the assembly of tight junctions in endothelial cells by upregulating proteins like claudin-5 and occludin. For instance, SHH signaling from astrocytes activates the Patched-1 (PTCH1) and Smoothened (SMO) receptors on endothelial cells, enhancing barrier integrity independently of pericytes.[99] VEGF, while potentially increasing permeability at high levels, works in concert with angiopoietin-1 to stabilize junctions when secreted by astrocytes.[100] In addition to structural support, astrocytes maintain ion and water homeostasis at the BBB through polarized expression of aquaporin-4 (AQP4) channels in their endfeet, which facilitate water movement and prevent edema formation. AQP4 is anchored to the perivascular basal lamina via interactions with laminins and dystrophin-associated proteins, ensuring its localization for efficient osmoregulation.[101] Coupled with inward-rectifying potassium channels (Kir4.1), AQP4 enables potassium siphoning, where excess K⁺ from synaptic activity is taken up by astrocytic processes and redistributed to perivascular spaces, thereby stabilizing extracellular ionic balance and protecting the BBB from osmotic stress. This mechanism is essential for controlling brain edema and maintaining the electrochemical environment necessary for neuronal function. Furthermore, the polarized localization of AQP4 in astrocytic perivascular endfeet is essential for the glymphatic system, which facilitates the clearance of soluble waste products, metabolites, and neurotoxic proteins (such as amyloid-beta) from the brain parenchyma via convective exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF) along perivascular spaces. Glymphatic activity is substantially increased during sleep, with an approximately 60% expansion of the extracellular space volume and reduced noradrenergic tone enabling enhanced waste removal, contributing to one of the restorative functions of sleep and overall brain homeostasis.[102][103] Astrocytes also regulate nutrient transport across the BBB by inducing the expression of key transporters in endothelial cells, ensuring selective passage of essential molecules while excluding toxins. They promote the upregulation of glucose transporter 1 (GLUT1) on the endothelial luminal membrane via secreted factors like transforming growth factor-β (TGF-β), facilitating glucose influx to meet cerebral energy demands.[98] Similarly, astrocytes drive the expression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp/ABCB1), through signaling pathways involving leukemia inhibitory factor (LIF), enabling active efflux of waste products and xenobiotics to maintain brain homeostasis.[100] The developmental maturation of the BBB coincides with the extension and coverage of astrocytic endfeet on vessels, a process that begins in late embryonic stages in rodents, with significant coverage achieved by embryonic day 18 (E18), leading to enhanced tight junction formation and transporter expression.[104] In humans, this process extends into the postnatal period, with full endfeet ensheathment occurring over months to years, reflecting the more protracted neurovascular development. Recent human induced pluripotent stem cell (iPSC) models have revealed delays in astrocyte endfeet formation and BBB maturation in neurodevelopmental disorders, such as Huntington's disease, where impaired WNT signaling disrupts barrier induction.[105]

Immune and Inflammatory Roles

Astrocytes contribute to immune surveillance in the central nervous system (CNS) by acting as antigen-presenting cells during inflammatory conditions. Under stimulation by interferon-gamma (IFNγ) from T helper 1 (Th1) cells, astrocytes upregulate major histocompatibility complex (MHC) class I and II molecules, enabling them to present antigens to CD8+ and CD4+ T cells, respectively.[106] This process facilitates direct interactions between astrocytes and T cells, which can amplify or modulate immune responses depending on the context.[106] Additionally, activated astrocytes release pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), often triggered by T cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF), thereby promoting neuroinflammation and potentially exacerbating CNS pathology.[106] In response to CNS injury or infection, astrocytes undergo reactive astrogliosis, a dynamic process characterized by cellular hypertrophy and upregulation of glial fibrillary acidic protein (GFAP).[107] This transformation involves morphological changes, including thickened processes and increased cell body size, mediated by signaling pathways such as signal transducer and activator of transcription 3 (STAT3) and cytokine triggers like IL-6.[107] Reactive astrocytes proliferate and migrate to form glial scars that physically isolate damaged tissue, limiting the spread of inflammatory mediators and immune cells while preserving surrounding healthy areas.[107] Although beneficial in the acute phase for containing injury, prolonged glial scarring can impede axonal regeneration and neural repair.[107] Astrocytes also participate in the complement system, primarily by synthesizing complement component 3 (C3), which plays a key role in synaptic pruning and immune modulation.[108] C3 deposited on synapses tags them for elimination by microglia via complement receptor 3 (CR3), a process essential for refining neural circuits during development and homeostasis.[108] Furthermore, astrocyte-derived C3 and its activation products, such as C3a, enhance microglial chemotaxis and activation, thereby coordinating glial responses to maintain CNS immune balance or amplify inflammation as needed.[108] Recent studies have highlighted astrocyte heterogeneity in neuroinflammatory contexts, particularly in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a 2025 cohort analysis of COVID-19 patients, SARS-CoV-2 infection of human induced pluripotent stem cell-derived astrocytes induced heterogeneous pro-inflammatory responses, including elevated IL-6 and IL-15 expression alongside increased apoptosis, contributing to neurological symptoms like brain fog and headaches without requiring viral replication.[109] Sex differences further influence astrocyte-mediated immune responses, with males often displaying heightened inflammatory profiles. For instance, male astrocytes exhibit stronger cytokine production (e.g., higher IL-6, TNF-α, and IL-1β) following lipopolysaccharide (LPS) exposure compared to females, while estrogen in females attenuates TNF-α and IL-18 expression during inflammation.[110] In injury models like stroke, female astrocytes show more frequent calcium signaling events, and aged females display elevated chemokine levels, underscoring sex-specific vulnerabilities in astrocyte reactivity.[110]

Role in Disease

Astrocytomas

Astrocytomas are a diverse group of primary brain tumors that arise from astrocytes or their precursor cells, representing the most common type of glioma. These tumors span a spectrum from low-grade forms, such as pilocytic astrocytoma classified as WHO CNS grade 1, to high-grade malignancies like glioblastoma (GBM), designated as WHO CNS grade 4.[111][112] Low-grade astrocytomas, including pilocytic variants, typically exhibit circumscribed growth and are more prevalent in children, while high-grade forms such as GBM demonstrate aggressive, infiltrative behavior predominantly in adults.[113][114] The origin of astrocytomas is linked to genetic alterations in astrocyte precursors, with mutations in the IDH1 gene serving as an early driver event in the development of most low- and intermediate-grade tumors.[115] IDH1 mutations, particularly the R132H variant, occur in over 70% of grade 2 and 3 astrocytomas, promoting metabolic reprogramming that facilitates neoplastic transformation from glial progenitors.[116] In contrast, IDH-wildtype astrocytomas, including the majority of GBMs, arise de novo without these mutations and are associated with rapid progression.[112] Astrocytomas account for approximately 30% of all gliomas, with GBM comprising the largest subset among malignant cases.[111] Pathophysiologically, astrocytomas are characterized by uncontrolled cellular proliferation due to dysregulated signaling pathways, such as those involving EGFR and PTEN, leading to hyperactivation of PI3K/AKT and MAPK cascades.[117] Tumor cells extend invasive processes along white matter tracts and the brain's perivascular spaces, evading immune surveillance and contributing to recurrence.[118] Additionally, tumor-associated astrocytes and glioma cells secrete vascular endothelial growth factor (VEGF), which drives pathological angiogenesis by stimulating endothelial cell proliferation and new vessel formation, thereby supporting the tumor's hypoxic microenvironment and metastatic potential.[119] This angiogenic switch is particularly pronounced in high-grade astrocytomas, where VEGF expression correlates with increased vascular permeability and edema.[120] The World Health Organization (WHO) 2021 classification integrates histopathological features with molecular markers for precise grading of astrocytomas, emphasizing IDH mutation status, 1p/19q codeletion, and histone H3 variants to distinguish astrocytoma subtypes from oligodendrogliomas.[112] For instance, IDH-mutant astrocytomas are graded from 2 to 4 based on features like mitotic activity and microvascular proliferation, while IDH-wildtype diffuse astrocytic tumors with specific alterations (e.g., EGFR amplification) are directly classified as GBM, grade 4.[121] MGMT promoter methylation, though not definitional for grading, serves as a key molecular marker predicting response to alkylating agents like temozolomide, with methylated status associated with improved outcomes in GBM patients.[122][123] Epidemiologically, astrocytomas predominantly affect adults, with peak incidence in the 45-65 age group for high-grade forms, and they constitute a significant burden due to limited therapeutic efficacy.[111] For GBM, the median survival remains approximately 15 months even with standard treatment involving surgery, radiotherapy, and temozolomide chemotherapy, highlighting the tumor's resistance and infiltrative nature.[124] In some contexts, the glial fibrillary acidic protein expression and hypertrophic morphology in astrocytomas mimic reactive gliosis, underscoring shared molecular pathways in astrocyte responses to injury.[112]

Neurodevelopmental Disorders

Astrocytes play a critical role in brain development, and their dysfunction contributes to various neurodevelopmental disorders, including autism spectrum disorder (ASD) and Rett syndrome. Postmortem examinations of individuals with ASD have revealed reduced astrocyte density in the prefrontal cortex, alongside signs of increased astrocyte activation, potentially disrupting synaptic connectivity and neuronal communication.[125] In Rett syndrome, mutations in the MECP2 gene lead to astrocyte abnormalities, including altered expression of glial fibrillary acidic protein (GFAP), a key marker of astrocyte structure and function; MeCP2 deficiency in astrocytes impairs their support for neuronal health and exacerbates disease progression.[126] These findings highlight how early disruptions in astrocyte maturation and density during development can precipitate long-term neurodevelopmental impairments. Mechanistically, astrocyte abnormalities in these disorders often involve deficits in gliotransmission, which hinder critical processes such as neuronal migration and synaptic pruning. For instance, impaired release of gliotransmitters like ATP from astrocytes disrupts signaling in the medial prefrontal cortex, contributing to social interaction deficits observed in ASD models.[127] Within the tripartite synapse model—where astrocytes form a functional unit with pre- and postsynaptic neurons—dysfunctional astrocytes alter synapse formation by failing to properly regulate excitatory/inhibitory balance, leading to excessive or immature synaptic connections that underlie behavioral phenotypes in neurodevelopmental disorders.[128] Evidence from animal models supports these associations; for example, astrocyte-specific conditional knockout of the IP3R2 gene, which impairs calcium signaling essential for gliotransmission, results in mice exhibiting ASD-like behaviors such as reduced social interaction and increased repetitive actions.[129] Similarly, MeCP2-deficient astrocytes in Rett syndrome models demonstrate reduced support for synaptogenesis due to aberrant secretion of factors like interleukin-6, mimicking core symptoms of the disorder.[130] Recent genetic studies from 2023 to 2025 have further linked variants in the NR2F1 gene, which regulates astrocyte development through transcription factors influencing cell-intrinsic pathways, to neurodevelopmental disorders with schizophrenia precursors, including intellectual disability and psychosis-like features in Bosch-Boonstra-Schaaf optic atrophy syndrome.[131]

Chronic Pain

Astrocytes play a pivotal role in the development and maintenance of chronic pain through reactive gliosis, particularly in the spinal cord dorsal horn, where they upregulate glial fibrillary acidic protein (GFAP) and release pro-inflammatory chemokines such as tumor necrosis factor-alpha (TNF-α). This upregulation amplifies nociceptive signaling by enhancing neuronal excitability and synaptic transmission, contributing to pain hypersensitivity.[132][133] In spinal astrocytes, GFAP expression increases following peripheral nerve injury or inflammation, leading to morphological changes like hypertrophy and process retraction, which facilitate the release of these chemokines to neighboring neurons and microglia.[134] TNF-α, in particular, sensitizes pain pathways by binding to receptors on dorsal horn neurons, promoting long-term potentiation and central pain amplification.[135] Chronic pain involves distinct astrocyte-mediated states depending on the etiology: inflammatory pain features rapid gliosis with acute cytokine release, while neuropathic pain exhibits persistent astrocyte hyperactivity driven by ATP signaling. In inflammatory models, such as those induced by carrageenan, astrocytes undergo swift activation, releasing TNF-α and interleukin-1β within hours to days, exacerbating peripheral and central sensitization.[136] Conversely, in neuropathic conditions like spinal nerve ligation, astrocytes maintain elevated ATP release via channels like pannexin-1, sustaining gliotransmitter spillover and neuronal hyperexcitability over weeks, which prolongs pain states.[137] This ATP-dependent hyperactivity distinguishes neuropathic pain by fostering a feed-forward loop of astrocyte-neuron communication, independent of the initial injury.[138] Key pathways involve astrocyte gliotransmission that enhances N-methyl-D-aspartate (NMDA) receptor activity in the dorsal horn, culminating in central sensitization. Activated astrocytes release glutamate and D-serine, which bind to NMDA receptors on postsynaptic neurons, lowering the threshold for synaptic activation and amplifying nociceptive inputs.[139] A core model posits that peripheral stimuli trigger astrocyte activation, prompting substance P release from primary afferents; this neuropeptide further stimulates astrocytes via neurokinin-1 receptors, leading to enhanced gliotransmitter output and persistent synaptic strengthening.[140] This cycle underlies central sensitization, where normal touch evokes pain (allodynia), as astrocytes bridge peripheral signals to prolonged neuronal changes.[141] Evidence from preclinical studies in the 2000s demonstrated that inhibiting astrocyte gliosis reduces chronic pain behaviors, as seen with minocycline, a tetracycline antibiotic that suppresses microglial and astrocytic activation. For instance, intrathecal minocycline administration in rat models of neuropathic pain attenuated mechanical allodynia by blocking GFAP upregulation and cytokine release in spinal astrocytes. In human studies, functional magnetic resonance imaging (fMRI) reveals correlates of astrocyte involvement in fibromyalgia, a chronic widespread pain disorder, through altered blood-oxygen-level-dependent (BOLD) signals linked to glial calcium waves and neuroinflammation in pain-processing regions like the insula and anterior cingulate cortex.[142] These findings underscore astrocytes' therapeutic potential in modulating chronic pain persistence.[143]

Neurodegenerative Diseases

Astrocytes play a pivotal role in the pathogenesis of neurodegenerative diseases through dysregulated reactivity and impaired supportive functions, contributing to neuronal damage and disease progression. In conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD), astrocyte dysfunction exacerbates neuroinflammation, disrupts clearance mechanisms, and promotes excitotoxicity, highlighting their transition from neuroprotective to neurotoxic states.[144] Recent human induced pluripotent stem cell (iPSC)-derived models have revealed sex-biased astrocyte reactivity, with female-derived astrocytes exhibiting heightened inflammatory responses and mitochondrial alterations in AD and ALS contexts, underscoring the influence of biological sex on glial contributions to neurodegeneration.[145][146] In Alzheimer's disease, reactive astrocytes adopt a pro-inflammatory A1 phenotype that promotes neuroinflammation by secreting cytokines such as IL-1β and TNF-α, which correlate with cognitive decline and plaque-associated neuronal loss.[147] This A1 subtype is induced by microglial signals including C1q, TNF, and IL-1α, leading to the upregulation of neurotoxic factors that amplify synaptic dysfunction and tau pathology.[144] Additionally, astrocyte-mediated clearance of amyloid-β (Aβ) fails due to reduced phagocytosis, as Aβ oligomers impair the uptake and degradation of dystrophic synapses by astrocytes, resulting in extracellular Aβ accumulation and plaque formation.[148] Depletion of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytes further disrupts Aβ endocytosis, exacerbating the imbalance between production and clearance.[149] In amyotrophic lateral sclerosis, astrocytes expressing mutant superoxide dismutase 1 (SOD1), such as the G85R variant, release toxic factors that induce motor neuron death via glutamate-mediated excitotoxicity.[150] These mutant astrocytes exhibit gain-of-function toxicity, including elevated D-serine levels that co-activate NMDA receptors, and fail to buffer extracellular glutamate effectively.[151] A key mechanism involves the loss of the excitatory amino acid transporter 2 (EAAT2), observed in 60-70% of sporadic ALS cases, where post-transcriptional defects reduce glutamate uptake by up to 95% in affected spinal cord regions, heightening vulnerability to excitotoxic damage.[152][153] Emerging research highlights aquaporin-4 (AQP4) in astrocytes as a therapeutic target, with mislocalization impairing glymphatic clearance of toxic proteins; preclinical models suggest modulating AQP4 polarization could mitigate ALS progression, though clinical translation remains in early stages as of 2024.[154] In Parkinson's disease, astrocytes facilitate the propagation of alpha-synuclein aggregates, taking up and releasing pathological oligomers that seed further misfolding in dopaminergic neurons, thereby accelerating Lewy body formation and spread.[155] This intercellular transmission is mediated by vesicular release from reactive astrocytes, which also show impaired uptake of alpha-synuclein compared to healthy states.[156] Furthermore, astrocyte dysfunction disrupts dopamine metabolism support, with PD patient-derived astrocytes displaying elevated alpha-synuclein expression and altered mitochondrial bioenergetics that reduce glutathione supply and antioxidant defense to neurons, promoting oxidative stress and dopaminergic degeneration.[157] Loss of ATP13A2 in astrocytes compromises lysosomal degradation of alpha-synuclein, further impairing clearance and exacerbating neurotoxicity.[158]

Other Pathologies

In hepatic encephalopathy, a condition arising from liver dysfunction, astrocytes undergo characteristic morphological changes, manifesting as hypertrophied, inclusion-laden cells known historically as Gomori-positive astrocytes, which indicate metabolic stress and were first described in the 1940s using chrome alum hematoxylin staining techniques.[159] These cells, often referred to as Alzheimer type II astrocytes, feature enlarged nuclei with prominent nucleoli and cytoplasmic inclusions, reflecting impaired glutamine metabolism and osmotic dysregulation.[160] Ammonia accumulation in hepatic encephalopathy induces astrocyte swelling through excessive glutamine synthesis via glutamine synthetase, leading to osmotic imbalance and cytotoxic brain edema.[161] This swelling compromises astrocyte functions, including glutamate uptake and ion homeostasis, exacerbating neuropsychiatric symptoms and potentially progressing to coma.[162] Cytokines further potentiate this ammonia-induced swelling, amplifying inflammatory responses and contributing to low-grade cerebral edema even in chronic cases.[163] Following stroke or traumatic brain injury, astrocytes enter a state of reactive astrogliosis, forming glial scars that initially contain damage but ultimately inhibit axonal regeneration by creating physical and molecular barriers.[164] These scars, composed of upregulated extracellular matrix proteins like chondroitin sulfate proteoglycans, impede neurite outgrowth and synaptic remodeling in the peri-injury zone.[165] In addition, reactive astrocytes may promote post-traumatic epilepsy through mechanisms involving neuronal hypersynchronization, where dysregulated gliotransmission and potassium buffering facilitate aberrant network activity.[166][167] Recent 2025 research highlights astrocytes' involvement in long COVID-associated brain fog, where persistent neuroinflammation triggers astrocyte activation, leading to glutamatergic dysregulation and cognitive impairment.[109] This chronic astrocytic response, characterized by elevated cytokine signaling and blood-brain barrier permeability, sustains microglial activation and synaptic dysfunction months post-infection.[168]

Research Directions

Current Studies

Recent advances in astrocyte research have leveraged single-cell RNA sequencing to uncover significant heterogeneity among astrocyte populations, revealing distinct subtypes based on transcriptional profiles across brain regions. For instance, the Zeisel et al. atlas from 2018 identified four broad astrocyte types across the mouse brain, with subsequent analyses like Batiuk et al. (2020) identifying five region-specific subtypes in the cortex and hippocampus.[169][53] Additionally, 2022 CRISPR interference screens in human iPSC-derived astrocytes have pinpointed genetic regulators of reactive state transitions, such as those involving NF-κB pathways, enabling targeted manipulation of astrocyte responses to inflammatory cues.[170] Imaging techniques have advanced the study of astrocyte dynamics in vivo, with two-photon microscopy enabling real-time visualization of calcium signaling in intact brain tissue. This approach has revealed spatially restricted calcium waves in cortical astrocytes during sensory processing, correlating with neuronal activity patterns.[171] Complementing this, optogenetics has been employed to selectively activate or inhibit astrocyte calcium channels, demonstrating their role in modulating gliotransmission—such as ATP release that influences synaptic plasticity—without confounding neuronal effects.[172] Model systems have expanded to include human induced pluripotent stem cell (iPSC)-derived astrocytes, which recapitulate patient-specific dysfunctions in neurodegenerative models like Alzheimer's disease, showing altered inflammatory profiles.[173] In parallel, zebrafish models have provided insights into astrocyte development and their interactions with vascular networks.[174][175] Key findings from post-2020 studies emphasize astrocytes as central hubs in brain network oscillations, with 2023 electroencephalography (EEG) correlations linking astrocytic calcium rhythms to slow-wave sleep periodicity in rodents.[176] Furthermore, research has highlighted enhanced astrocyte-neuron metabolic coupling, where astrocytes supply lactate via the astrocyte-neuron lactate shuttle to support high-energy demands during synaptic activity and plasticity.[177]

Therapeutic Potential

Astrocytes represent a compelling target for therapeutic interventions in neurological disorders, leveraging their roles in maintaining synaptic homeostasis, regulating inflammation, and supporting neuronal survival. Strategies focusing on astrocytes aim to mitigate pathological processes such as excitotoxicity, edema, and gliosis, with several approaches advancing from preclinical models to clinical evaluation. Enhancing astrocyte-mediated glutamate uptake via excitatory amino acid transporter 2 (EAAT2) has been explored as a treatment for amyotrophic lateral sclerosis (ALS), where reduced EAAT2 expression contributes to motor neuron degeneration. Ceftriaxone, a beta-lactam antibiotic, upregulates EAAT2 levels in astrocytes, thereby increasing glutamate clearance. In a multi-phase clinical trial conducted from 2009 to 2013 involving 458 ALS patients, intravenous ceftriaxone at 2 g twice daily was well-tolerated over 96 weeks but failed to significantly prolong survival or slow functional decline compared to placebo, highlighting challenges in translating preclinical benefits to human outcomes.[178] Modulation of aquaporin-4 (AQP4), the primary water channel in astrocytic endfeet, offers potential for managing brain edema following ischemic stroke. AQP4 facilitates water movement across the blood-brain barrier, exacerbating cytotoxic edema in the acute phase while aiding resolution in vasogenic edema later. Preclinical rodent models demonstrate that selective AQP4 inhibitors, such as TGN-020, administered within 1 hour of stroke onset, significantly reduce edema and infarct size (e.g., by 25-35%) by blocking water influx into astrocytes.[179] Similarly, trifluoperazine inhibits AQP4 polarization to perivascular membranes, decreasing swelling in early injury models without impairing long-term fluid clearance.[180] These findings underscore the need for time-sensitive, phase-specific modulation, though no AQP4-targeted therapies have yet reached human trials. Gene therapy targeting astrocytes holds promise for neurodevelopmental disorders like Rett syndrome, where mutations in the MECP2 gene impair astrocyte function, leading to synaptic dysfunction and seizures. Adeno-associated virus (AAV) vectors driven by astrocyte-specific glial fibrillary acidic protein (GFAP) promoters enable selective MECP2 delivery to restore gene expression in glia. Preclinical studies in mouse models show that astrocyte-restricted MECP2 re-expression via GFAP-Cre systems ameliorates motor deficits and significantly extends lifespan (e.g., from ~3 to 7.5 months).[181] Building on this, phase I/II clinical trials initiated in 2023, such as Neurogene's NGN-401 (an AAV9-MECP2 vector with self-regulating EXACT technology), evaluate safety and tolerability in pediatric Rett patients to minimize toxicity. In 2025, interim data showed improved symptoms in low-dose cohorts but safety concerns in high-dose groups (as of November 2025).[182][183] Stem cell-based therapies involving induced pluripotent stem cell (iPSC)-derived astrocytes aim to replace dysfunctional glia and promote repair in traumatic and oncological conditions. In spinal cord injury models, transplantation of human iPSC-derived astrocytes into the contused cervical region of rodents results in high graft survival, maturation into GFAP-positive cells, and preservation of phrenic motor neuron innervation, leading to improved diaphragm electromyography amplitudes and respiratory function.[184] For glioblastoma multiforme (GBM), iPSC-derived astrocytes are being investigated for their potential to modulate the tumor microenvironment, though clinical translation remains limited due to challenges like immune rejection and tumorigenicity.[185] Emerging nanoparticle-based delivery systems enable selective modulation of astrocytes in chronic pain states, where astrocytic activation amplifies central sensitization. In 2025 preclinical studies, nanozymes—nanomaterials mimicking antioxidant enzymes—target oxidative stress in spinal astrocytes, scavenging reactive oxygen species to suppress neuroinflammation and reduce mechanical hypersensitivity in neuropathic pain models.[186] These carriers, often lipid or polymeric nanoparticles conjugated with astrocyte-specific ligands like GFAP antibodies, improve drug bioavailability across the blood-brain barrier while minimizing off-target effects. Human trials raise ethical concerns, including equitable access, long-term genomic integration risks, and informed consent for vulnerable populations with chronic conditions, necessitating robust oversight frameworks.[187]

References

  1. Astrocytes: biology and pathology - PMC - PubMed Central
  2. Astrocytes in the central nervous system and their functions in health ...
  3. The role of astrocyte structural plasticity in regulating neural circuit ...
  4. Astrocyte morphology: Diversity, plasticity, and role in neurological ...
  5. Astrocyte plasticity in mice ensures continued endfoot coverage of ...
  6. An Early History of Neuroglial Research: Personalities - MDPI
  7. Astrocyte morphology - ScienceDirect.com
  8. Protoplasmic Astrocytes in CA1 Stratum Radiatum Occupy Separate ...
  9. Astrocytes in human central nervous system diseases: a frontier for ...
  10. Astrocytes: The Housekeepers and Guardians of the CNS - PMC
  11. Beyond the GFAP-Astrocyte Protein Markers in the Brain - MDPI
  12. S100B is selectively expressed by gray matter protoplasmic ...
  13. Astrocytes in Oligodendrocyte Lineage Development and White ...
  14. The glial framework reveals white matter fiber architecture in human ...
  15. Astrocyte Form and Function in the Developing CNS - PMC
  16. Morphological and physiological features of human cerebral cortical ...
  17. Heterogeneity of Astrocytic Form and Function - PMC
  18. Radial Glia Cells in the Developing Human Brain - PMC
  19. Radial Glial Cells: Are They Really Glia? - ScienceDirect.com
  20. Asymmetric Inheritance of Radial Glial Fibers by Cortical Neurons
  21. Developmental and Evolutionary Adaptations of Cortical Radial Glia
  22. Neural Stem Cells Direct Axon Guidance via Their Radial Fiber ...
  23. GFAPδ Expression in Glia of the Developmental and Adolescent ...
  24. Bergmann glial development in the mouse cerebellum as revealed ...
  25. Radial glia and radial glia-like cells: Their role in neurogenesis and ...
  26. Mechanisms of radial glia progenitor cell lineage progression - PMC
  27. Both oligodendrocytes and astrocytes develop from progenitors in ...
  28. GFAP at 50 - PMC - PubMed Central - NIH
  29. A Guide to Astrocyte Markers | Biocompare
  30. Astrocyte Markers - Antibodies.com
  31. two types of astrocytes in cultures of developing rat
  32. Type 1 Astrocyte - an overview | ScienceDirect Topics
  33. Astrocytes: biology and pathology | Acta Neuropathologica
  34. Single-Cell RNA-Sequencing in Astrocyte Development ...
  35. White matter astrocytes in health and disease - PMC - PubMed Central
  36. Histology, Astrocytes - StatPearls - NCBI Bookshelf - NIH
  37. Heterogeneity and Development of Fine Astrocyte Morphology ...
  38. Astrocyte–Neuron Networks: A Multilane Highway of Signaling for ...
  39. Reappraisal of Bergmann glial cells as modulators of cerebellar ...
  40. Reactive changes of retinal astrocytes and Müller glial cells in ...
  41. Human and mouse cortical astrocytes: a comparative view from ...
  42. Evolution of increased glia–neuron ratios in the human frontal cortex
  43. Human and mouse cortical astrocytes: a comparative view from ...
  44. The Regulation of Astrocytic Glutamate Transporters in Health and ...
  45. Role of Astrocytic Inwardly Rectifying Potassium (Kir) 4.1 Channels ...
  46. It's All about Timing: The Involvement of Kir4.1 Channel Regulation ...
  47. Revealing the contribution of astrocytes to glutamatergic neuronal ...
  48. G protein-coupled receptor signalling in astrocytes in health and ...
  49. GABAergic‐astrocyte signaling: A refinement of inhibitory brain ...
  50. An autocrine purinergic signaling controls astrocyte-induced ...
  51. G-PROTEIN-COUPLED RECEPTORS IN ASTROCYTE-NEURON ...
  52. Identification of region-specific astrocyte subtypes at single cell ...
  53. Aquaporin-4 Water Channel in the Brain and Its Implication for ...
  54. Connexin43 and Its Regulation of Astrocyte Gap Junction Function
  55. The Multifaceted Role of Astrocyte Connexin 43 in Ischemic Stroke ...
  56. Early Neuronal and Glial Fate Restriction of Embryonic Neural Stem ...
  57. Neurogenesis in Embryos and in Adult Neural Stem Cells - PMC
  58. Context-dependent regulation of Notch signaling in glial ...
  59. Sox9 and NFIA Coordinate a Transcriptional Regulatory Cascade ...
  60. The Transcription Factor NFIA Controls the Onset of Gliogenesis in ...
  61. Astrocytes and disease: a neurodevelopmental perspective
  62. Local generation of glia is a major astrocyte source in postnatal cortex
  63. https://doi.org/10.1038/nature10959
  64. Astrocytogenesis: where, when, and how - PMC - PubMed Central
  65. Understanding astrocyte differentiation: Clinical relevance, technical ...
  66. BMP Signaling in Astrocytes Downregulates EGFR to Modulate ...
  67. TGF-β as a Key Modulator of Astrocyte Reactivity - PubMed Central
  68. Regulation of Gene Expression by Thyroid Hormone in Primary ...
  69. Differential Proliferation and Maturation of Subcortical Astrocytes ...
  70. Region-Specific Differences in Morphometric Features and Synaptic ...
  71. Brain stars take the lead during critical periods of early postnatal ...
  72. Sex-Specific Properties of Astrocytes: From Development to Evolutionary Insights - Neurochemical Research
  73. Astrocyte development—More questions than answers - PMC
  74. Astrocytes Control Synapse Formation, Function, and Elimination
  75. Astrocytes as a Source for Extracellular Matrix Molecules and ...
  76. Tripartite synapses: glia, the unacknowledged partner - ScienceDirect
  77. Astrocytes locally translate transcripts in their peripheral processes
  78. Channels and Transporters in Astrocyte Volume Regulation in ...
  79. Calcium signaling in astrocytes and gliotransmitter release - Frontiers
  80. Specialized astrocytes mediate glutamatergic gliotransmission in the ...
  81. SNARE Protein-Dependent Glutamate Release from Astrocytes
  82. Multiple Lines of Evidence Indicate That Gliotransmission Does Not ...
  83. Vesicular Glutamate Transporter-Dependent Glutamate Release ...
  84. Neuronal adenosine release, and not astrocytic ATP release ... - PNAS
  85. mGluR5 stimulates gliotransmission in the nucleus accumbens - PNAS
  86. Brain Energy Metabolism: Focus on Astrocyte-Neuron Metabolic ...
  87. Direct evidence for activity-dependent glucose phosphorylation in ...
  88. The Role of Brain Glycogen in Supporting Physiological Function
  89. Astrocytic glycogen-derived lactate fuels the brain during ... - PNAS
  90. Oligodendroglial myelination requires astrocyte-derived lipids
  91. Cholesterol metabolism and homeostasis in the brain | Protein & Cell
  92. Metabolic Reprogramming of Astrocytes in Pathological Conditions
  93. Mitochondrial dynamics in health and disease: mechanisms ... - Nature
  94. https://doi.org/10.1101/cshperspect.a020412
  95. https://doi.org/10.1126/science.1206936
  96. https://doi.org/10.1038/nrn1824
  97. https://doi.org/10.1038/ncomms4413
  98. https://doi.org/10.1038/325253a0
  99. https://doi.org/10.1016/j.celrep.2017.04.021
  100. Functional immune cell–astrocyte interactions - PMC
  101. Astrocyte Reactivity and Reactive Astrogliosis: Costs and Benefits
  102. The Role of Complement in Synaptic Pruning and Neurodegeneration
  103. Astroglia-mediated neuroinflammation as a putative mechanism of ...
  104. Sex-Specific Properties of Astrocytes: From Development to ...
  105. Astrocytoma - StatPearls - NCBI Bookshelf - NIH
  106. The 2021 WHO Classification of Tumors of the Central Nervous ...
  107. Pilocytic astrocytoma | Radiology Reference Article | Radiopaedia.org
  108. Glioblastoma: Practice Essentials, Background, Pathophysiology
  109. IDH1 mutations are early events in the development of astrocytomas ...
  110. IDH1 and IDH2 Mutations in Gliomas
  111. Glioblastoma multiforme: insights into pathogenesis, key signaling ...
  112. Gliomas Biology: Angiogenesis and Invasion - IntechOpen
  113. Novel insights into astrocyte-mediated signaling of proliferation ...
  114. How Does the Oncogene Astrocyte Elevated gene-1 (AEG-1 ...
  115. Adult type diffuse gliomas in the new 2021 WHO Classification - PMC
  116. Major Features of the 2021 WHO Classification of CNS Tumors - PMC
  117. Extent and prognostic value of MGMT promotor methylation ... - Nature
  118. Radiotherapy plus Concomitant and Adjuvant Temozolomide for ...
  119. Decreased number and increased activation state of astrocytes in ...
  120. MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis ...
  121. The Role of Neuroglia in Neurodevelopmental Disorders and ... - MDPI
  122. Astrocyte-neuron crosstalk in neurodevelopmental disorders
  123. Impaired calcium signaling in astrocytes modulates autism spectrum ...
  124. Mecp2 knock-out astrocytes affect synaptogenesis by interleukin 6 ...
  125. A pathogenic NR2F1 gene variant disrupts transcriptional activity ...
  126. Astrocytes in Chronic Pain: Cellular and Molecular Mechanisms - PMC
  127. An update on reactive astrocytes in chronic pain
  128. Reactive Astrocytes: Critical Players in the Development of Chronic ...
  129. Spinal injection of TNF-α-activated astrocytes produces persistent ...
  130. Reactive Astrocytes: Critical Players in the Development of Chronic ...
  131. Astrocytes in Chronic Pain: Cellular and Molecular Mechanisms
  132. Pathological and protective roles of glia in chronic pain. - Europe PMC
  133. Glutamate‐mediated astrocyte‐to‐neuron signalling in the rat dorsal ...
  134. Gliotransmission modulates baseline mechanical nociception
  135. Neuroinflammation and central sensitization in chronic and ...
  136. Magnetic resonance imaging of neuroinflammation in chronic pain
  137. Brain glial activation in fibromyalgia – A multi-site positron emission ...
  138. Pathological phenotypes of astrocytes in Alzheimer's disease - Nature
  139. Cell type and sex specific mitochondrial phenotypes in iPSC derived ...
  140. Sex Differences in Astrocyte Activity - PMC - PubMed Central
  141. Astrocytes as Neuroimmunocytes in Alzheimer's Disease
  142. Amyloid‐β impairs the phagocytosis of dystrophic synapses by ...
  143. Amyloid β Clearance Is Disrupted by Depletion of Low-Density ...
  144. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes ...
  145. Astrocytes expressing ALS-linked mutated SOD1 release factors ...
  146. the Cause for Absent EAAT2, a Glutamate Transporter, in ...
  147. EAAT2 and the molecular signature of amyotrophic lateral sclerosis
  148. Aquaporin-4 mis-localization slows glymphatic clearance of α ...
  149. The Role of Astrocytes and Alpha-Synuclein in Parkinson's Disease
  150. Therapeutic functions of astrocytes to treat α-synuclein pathology in ...
  151. Metabolic alterations in Parkinson's disease astrocytes - Nature
  152. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein ...
  153. Gomori-positive astrocytes: biological properties and implications for ...
  154. The autophagic marker p62 highlights Alzheimer type II astrocytes in ...
  155. Astrocytes profiling in acute hepatic encephalopathy - PubMed Central
  156. Hepatic encephalopathy in chronic liver disease: a clinical ...
  157. Marked potentiation of cell swelling by cytokines in ammonia ...
  158. Astrocytes, reactive astrogliosis, and glial scar formation in traumatic ...
  159. Astrogliosis and glial scar in ischemic stroke - ScienceDirect.com
  160. Astrocytes as a target for therapeutic strategies in epilepsy - Frontiers
  161. The Role of Glial Cells in the Pathophysiology of Epilepsy - MDPI
  162. Brain fog in long COVID: A glutamatergic hypothesis with astrocyte ...
  163. Are we there yet? Exploring astrocyte heterogeneity one cell at a time
  164. Two-photon (2P) Microscopy to Study Ca2+ Signaling in Astrocytes ...
  165. Characterization of Optimal Optogenetic Stimulation Paradigms to ...
  166. A Modeling Paradigm for Alzheimer's Disease - PubMed Central - NIH
  167. Zebrafish glial-vascular interactions progressively expand over the ...
  168. Optogenetic targeting of astrocytes restores slow brain rhythm ...
  169. Neuron–astrocyte metabolic coupling facilitates spinal plasticity and ...
  170. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis
  171. Aquaporin-4 in Stroke and Brain Edema—Friend or Foe? - MDPI
  172. A role for glia in the progression of Rett syndrome - PMC - NIH
  173. https://clinicaltrials.gov/study/NCT05898620
  174. Human iPS cell-derived astrocyte transplants preserve respiratory ...
  175. Human iPSC-derived astrocytes transplanted into the mouse brain ...
  176. Nanozymes in neuropathic pain: strategies bridging oxidative stress ...
  177. Highlighting Their Potential as Therapeutic Targets for CNS Injury
  178. A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β
  179. Sleep Drives Metabolite Clearance from the Adult Brain
User Avatar
No comments yet.